Gilenya
/
Gilenya (fingolimod) is an oral medication classified as a sphingosine 1-phosphate receptor modulator, used to treat relapsing forms of multiple sclerosis (MS). It is taken as a once-daily oral capsule and is available by prescription only. Patients are advised to monitor for potential side effects, including bradycardia and elevated liver enzymes, and should not use Gilenya if they have a history of certain heart conditions or active infections.
Pay securely with Zelle
FAQs about Gilenya
How long does it take to work?
The onset of action for Gilenya (fingolimod) is not explicitly stated in the label. However, it is generally understood that the effects on reducing the frequency of relapses in multiple sclerosis may take several weeks to become apparent.
What should I do if I miss a dose?
If you miss a dose of Gilenya, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. This information is provided in the Patient Counseling Information section of the label.
Can I take Gilenya while pregnant or breastfeeding?
The label advises that Gilenya should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether fingolimod is excreted in human milk, so caution should be exercised when administering Gilenya to breastfeeding mothers.
Can I stop taking Gilenya suddenly?
The label warns against abrupt discontinuation of Gilenya, as this may lead to a rebound effect in multiple sclerosis symptoms. It is important to consult your healthcare provider before making any changes to your medication regimen.
How should I store Gilenya?
Gilenya should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). Keep the medication in its original container and protect it from moisture and light.
25
commonly-prescribed
medication.
🍪 We use cookies
We use cookies to enhance your browsing experience, serve personalised content, and analyse traffic. By clicking "Accept all", you consent to our use of cookies.